2544
Y. Tang et al.
PAPER
1H NMR (CDCl3): d = 1.22–1.36 (m, 2 H), 1.48–1.56 (m, 2 H), 1.62
(d, J = 5.6 Hz, 2 H), 1.70–1.80 (m, 3 H), 3.80 (d, J = 6.8 Hz, 2 H),
3.90–3.97 (m, 4 H), 6.88 (s, 1 H), 7.05 (s, 1 H), 7.43 (s, 1 H).
13C NMR (CDCl3): d = 27.6, 33.9, 38.0, 52.5, 64.2, 64.3, 108.4,
119.2, 129.4, 137.4.
J = 7.2 Hz, 2 H), 3.05 (m, 1 H), 3.72 (dd, J = 4.3, 13.7 Hz, 1 H), 3.94
(dd, J = 7.6, 13.7 Hz, 1 H), 6.94 (s, 1 H), 7.02 (s, 1 H), 7.49 (s, 1 H).
13C NMR (CDCl3): d = 12.2, 14.1, 43.2, 50.7, 56.2, 119.3, 128.9,
137.6.
HRMS–FAB: m/z [M + H]+ calcd for C10H20N3: 182.1657; found:
182.1655.
HRMS–FAB: m/z [M + H]+ calcd for C12H19N2O2: 223.1446;
found: 223.1434.
Acknowledgement
Reaction of Benzylic Alcohols with CDI to Form N-Alkylimida-
zoles 2; Typical Procedure
1-Benzhydryl-1H-imidazole (2k)
A mixture of 1k (184 mg, 1 mmol), CDI (210 mg, 1.3 mmol) and
NMP (10 mL) was heated at 170 °C for 1 h. After cooling to r.t., the
reaction mixture was diluted with EtOAc (30 mL) and washed with
H2O (2 × 20 mL), brine (20 mL) and dried over MgSO4. Filtration
and removal of solvents in vacuo afford 2k11 as a colorless solid
(178 mg, 80%).
We thank the Medicines for Malaria Venture (MMV) for generous
support of this research and the Nebraska Center for Mass Spectro-
metry for the HRMS data.
References
(1) Roth, H. J.; Kleeman, A. Pharmaceutical Chemistry; John
Wiley: New York, 1988, 218.
(2) (a) Rotstein, D. M.; Kertesz, D. J.; Walker, K. A. M.;
Swinney, D. C. J. Med. Chem. 1992, 35, 2818. (b) Jones, C.
D.; Winter, M. A.; Hirsch, K. S.; Stamm, N.; Taylor, H. M.;
Holden, H. E.; Davenport, J. D.; Krumkalns, E. V.; Suhr, R.
G. J. Med. Chem. 1990, 33, 416. (c) Heeres, J.; Backx, L. J.;
Mostmans, J. H.; Van Cutsem, J. J. Med. Chem. 1979, 22,
1003.
(3) (a) Amemiya, Y.; Terada, A.; Wachi, K.; Miyazawa, H.;
Hatakeyama, N.; Matsuda, K.; Oshima, T. J. Med. Chem.
1989, 32, 1265. (b) Hasegawa, T.; Yoshida, K.; Hachiya, K.;
Miyazaki, M.; Tsuruta, H.; Nambu, F.; Ohuchida, S.;
Kawamura, M. Synlett 1997, 511. (c) Kaulen, J. Angew.
Chem., Int. Ed. Engl. 1989, 28, 462; Angew. Chem.; 1989,
101, 507. (d) Kato, A.; Ikeda, Y.; Sugita, N.; Nitta, T.; Enari,
H.; Kashima, A.; Konno, M.; Niimura, K. Chem. Pharm.
Bull. 1995, 43, 2152.
Reaction of 3,4-Dimethylbenzyl 1H-Imidazole-1-carboxylate
with 2-Methylimidazole
1-(3,4-Dimethylbenzyl)-2-methyl-1H-imidazole (5e)
A mixture of 3,4-dimethylbenzyl 1H-imidazole-1-carboxylate (3e)
(230 mg, 1 mmol), 2-methylimidazole (420 mg, 5 mmol) and NMP
(10 mL) was heated at 170 °C for 16 h. After cooling to r.t., the re-
action mixture was diluted with EtOAc (30 mL) and washed with
H2O (2 × 20 mL), brine (20 mL) and dried over MgSO4. Filtration
and removal of solvents in vacuo afford a mixture of 2e6 and 5e
(1:4).
For 5e
1H NMR (CDCl3): d = 2.22 (s, 3 H), 2.23 (s, 3 H), 2.33 (s, 3 H), 4.95
(s, 2 H), 6.78 (d, J = 7.8 Hz, 1 H), 6.81 (s, 1 H), 6.83 (s, 1 H), 6.92
(s, 1 H), 7.08 (d, J = 7.8 Hz, 1 H).
13C NMR (CDCl3): d = 12.9, 19.2, 19.6, 49.3, 119.7, 124.0, 126.9,
133.5, 136.1, 144.6.
HRMS–FAB: m/z [M + H]+ calcd for C13H17N2: 201.1392; found:
201.1390.
(4) Njar, V. C. O. Synthesis 2000, 2019.
(5) Fischer, W. Synthesis 2002, 29.
(6) Kamijo, T.; Yamamoto, R.; Harada, H.; Iizuka, K. Chem.
Pharm. Bull. 1983, 31, 1213.
(7) Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller,
B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.;
Palzer, M. Arch. Pharm. Pharm. Med. Chem. 1997, 330,
141.
(8) Whitten, J. P.; McCarthy, J. R.; Matthews, D. P. Synthesis
1988, 470.
(9) Bertolini, G.; Pavich, G.; Vergani, B. J. Org. Chem. 1998,
63, 6031.
(10) Botta, M.; Summa, V.; Trapassi, G.; Monteagudo, E.;
Corelli, F. Tetrahedron: Asymmetry 1994, 5, 181.
(11) Ogata, M.; Matsumoto, H.; Kida, S.; Shimizu, S. Chem. Ind.
(London) 1980, 85.
Reaction of N,N-Disubstituted b-Aminoalcohols with CDI; Typ-
ical Procedure
N,N-Diethyl-2-(1H-imidazol-1-yl)propan-1-amine (8b) and
N,N-Diethyl-1-(1H-imidazol-1-yl)propan-2-amine (10b)
A mixture of 6b (400 mg, 3 mmol), CDI (582 mg, 3.6 mmol) and
EtOAc (20 mL) was refluxed overnight. After cooling to r.t., the re-
action mixture was washed with H2O (2 × 20 mL), brine (20 mL)
and dried over MgSO4. Filtration and removal of solvents in vacuo
afford a 1:3 mixture of 8b and 10b.
For 8b
1H NMR (CDCl3): d = 0.92 (t, J = 6.8 Hz, 3 H), 0.94 (t, J = 6.8 Hz,
3 H), 1.47 (d, J = 6.8 Hz, 3 H), 2.39 (q, J = 6.8 Hz, 2 H), 2.43–2.47
(m, 1 H), 2.53 (q, J = 6.8 Hz, 2 H), 2.55–2.59 (m, 1 H), 4.13–4.17
(m, 1 H), 6.95 (s, 1 H), 7.04 (s, 1 H), 7.54 (s, 1 H).
(12) Aelterman, W.; Lang, Y.; Willemsens, B.; Vervest, I.; Leurs,
S.; De Knaep, F. Org. Process Res. Dev. 2001, 5, 467.
(13) Cutugno, S.; Martelli, G.; Negro, L.; Savoia, D. Eur. J. Org.
Chem. 2001, 517.
13C NMR (CDCl3): d = 12.0, 19.2, 47.8, 53.0, 60.5, 116.6, 128.9,
(14) Adolphi, H.; Steimmig, A.; Spaenig, H. Fr. Patent FR
1486817 19670630, 1967; Chem. Abstr. 1968, 77228.
(15) O’Brien, P.; Towers, T. D. J. Org. Chem. 2002, 67, 304.
(16) Mulvihill, M. J.; Cesario, C.; Smith, V.; Beck, P.; Nigro, A.
J. Org. Chem. 2004, 69, 5124.
136.1.
HRMS–FAB: m/z [M + H]+ calcd for C10H20N3: 182.1657; found:
182.1655.
(17) Totleben, M. J.; Freeman, J. P.; Szmuszkovicz, J. J. Org.
Chem. 1997, 62, 7319.
(18) Freyne, E.; Raeymaekers, A.; Venet, M.; Sanz, G.; Wouters,
W.; De Coster, R.; Van Wauwe, J. Bioorg. Med. Chem. Lett.
1998, 8, 267.
For 10b
1H NMR (CDCl3): d = 0.96 (t, J = 7.2 Hz, 3 H), 0.97 (t, J = 7.2 Hz,
3 H), 0.98 (d, J = 6.8 Hz, 3 H), 2.41 (q, J = 7.2 Hz, 2 H) 2.56 (q,
Synthesis 2004, No. 15, 2540–2544 © Thieme Stuttgart · New York